Neovasc has announced that the clinical protocol for its COSIRA (coronary sinus reducer for treatment of refractory angina) trial has been published in the peer-reviewed journal Trials.
COSIRA is a double-blind, randomised, multicentre trial that is further assessing the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina. The COSIRA trial is currently enrolling patients in the UK, Europe and Canada.
“COSIRA was designed as a rigorous, sham-controlled study to provide definitive evidence of the efficacy of the Reducer device, and we are pleased that the protocol is being recognised as noteworthy by the clinical research community,” said Shmuel Banai, chief medical officer of Neovasc. “We are on target for completion of patient enrolment in the second quarter of 2013, with six-month follow-up data from all patients expected to be available around year’s end.”